Scholarlink

Background <p>This study aimed to identify the most effective drug therapeutics for patients with the mesenchymal subtype of advanced gastric cancer (AGC). Extensive research employing diverse omics methodologies has unveiled a varied landscape of AGC. Recent progress in next-generation sequencing and other genomic technologies has facilitated a more intricate exploration of AGC at the molecular level. Nonetheless, the optimal treatment for patients with the mesenchymal subtype of gastric cancer remains elusive. Lei’s molecular classification of AGC is based on gene expression profiles named “mesenchymal,” “immunogenic,” “classical,” and “metabolic.”</p> Patients and Methods <p>Based on RNA-seq transcriptome, 234 patients were divided into four molecular subtypes: mesenchymal (<i>n</i> = 96), immunogenic (<i>n</i> = 37), metabolic (<i>n</i> = 61), and classic (<i>n</i> = 40).</p> Results <p>Among those with mesenchymal-subtype AGC, compared with non-Apatinib group, the Apatinib treatment group demonstrated a significant increase in objective response rate (ORR 89.3% versus 69.3%, <i>p</i> = 0.038; odds ratio (OR) 0.269, 95% confidence interval (CI) (0.073–0.989)); overall survival (OS) 89.3% versus 60.2%, <i>p</i> = 0.010; hazard ratio (HR) 0.241, 95% CI (0.073–0.796)) and disease-free survival (DFS 78.6% versus 52.9%, <i>p</i> = 0.031; HR 0.400, 95% CI (0.167–0.956)). Furthermore, Apatinib significantly reduced the risk of death and recurrence in patients with mesenchymal subtype (OS: HR 0.129, 95% CI (0.030–0.563), <i>p</i> = 0.006; DFS: HR 0.340, 95% CI (0.138–0.833), <i>p</i> = 0.018). However, no significant differences were observed in the ORR, OS, or DFS between patients with metabolic and classical subtypes who underwent combination chemotherapy with additional Apatinib or camrelizumab.</p> Conclusions <p>Our analysis has revealed that, for neoadjuvant therapy in AGC, the mesenchymal subtype stands out as the ideal patient population benefiting from Apatinib.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Neoadjuvant Treatment Based on Gastric Cancer Molecular Subtyping: Chemotherapy, Immunotherapy, or Targeted Therapy?—A Retrospective Analysis

  • 期刊论文

  • 发表日期：

    2025年7月3日

查看全文
  • Hua-Long Zheng,
  • Li-Li Shen,
  • Qiao-Ling Zheng,
  • Jian-Xian Lin,
  • Chang-Ming Huang,
  • Zheng-Deng Lei,
  • Chao-Hui Zheng

摘要

Background

This study aimed to identify the most effective drug therapeutics for patients with the mesenchymal subtype of advanced gastric cancer (AGC). Extensive research employing diverse omics methodologies has unveiled a varied landscape of AGC. Recent progress in next-generation sequencing and other genomic technologies has facilitated a more intricate exploration of AGC at the molecular level. Nonetheless, the optimal treatment for patients with the mesenchymal subtype of gastric cancer remains elusive. Lei’s molecular classification of AGC is based on gene expression profiles named “mesenchymal,” “immunogenic,” “classical,” and “metabolic.”

Patients and Methods

Based on RNA-seq transcriptome, 234 patients were divided into four molecular subtypes: mesenchymal (n = 96), immunogenic (n = 37), metabolic (n = 61), and classic (n = 40).

Results

Among those with mesenchymal-subtype AGC, compared with non-Apatinib group, the Apatinib treatment group demonstrated a significant increase in objective response rate (ORR 89.3% versus 69.3%, p = 0.038; odds ratio (OR) 0.269, 95% confidence interval (CI) (0.073–0.989)); overall survival (OS) 89.3% versus 60.2%, p = 0.010; hazard ratio (HR) 0.241, 95% CI (0.073–0.796)) and disease-free survival (DFS 78.6% versus 52.9%, p = 0.031; HR 0.400, 95% CI (0.167–0.956)). Furthermore, Apatinib significantly reduced the risk of death and recurrence in patients with mesenchymal subtype (OS: HR 0.129, 95% CI (0.030–0.563), p = 0.006; DFS: HR 0.340, 95% CI (0.138–0.833), p = 0.018). However, no significant differences were observed in the ORR, OS, or DFS between patients with metabolic and classical subtypes who underwent combination chemotherapy with additional Apatinib or camrelizumab.

Conclusions

Our analysis has revealed that, for neoadjuvant therapy in AGC, the mesenchymal subtype stands out as the ideal patient population benefiting from Apatinib.